JP2015505309A - 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ - Google Patents

髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ Download PDF

Info

Publication number: JP2015505309A
Authority: JP; Japan
Prior art keywords: seq; amino acid; composition; antigen; fhbp
Prior art date: 2011-12-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2014549542A

Other languages

English (en)

Japanese (ja)

Other versions

JP2015505309A5 (2

Inventor

ベアトリーチェマリアアリコ，

ブルネルラブルネルリ，

マウリツィオコマンドゥッチ，

ピッツァ，　マリアグラツィア

マリアグラツィアピッツァ，

スィルヴァーナサヴィーノ，

マリアスカーセッリ，

Original Assignee

ノバルティスアーゲー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-29

Filing date

2011-12-29

Publication date

2015-02-19

2011-12-29 Application filed by ノバルティスアーゲー, ノバルティスアーゲー filed Critical ノバルティスアーゲー

2015-02-19 Publication of JP2015505309A publication Critical patent/JP2015505309A/ja

2015-04-02 Publication of JP2015505309A5 publication Critical patent/JP2015505309A5/ja

Status Pending legal-status Critical Current

Links

101710186862 Factor H binding protein Proteins 0.000 title claims abstract description 113
239000000203 mixture Substances 0.000 claims abstract description 139
239000002671 adjuvant Substances 0.000 claims abstract description 37
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 21
239000000427 antigen Substances 0.000 claims description 172
108091007433 antigens Proteins 0.000 claims description 171
102000036639 antigens Human genes 0.000 claims description 171
150000001720 carbohydrates Chemical class 0.000 claims description 109
125000003275 alpha amino acid group Chemical group 0.000 claims description 49
239000012634 fragment Substances 0.000 claims description 38
230000000844 anti-bacterial effect Effects 0.000 claims description 36
235000001014 amino acid Nutrition 0.000 claims description 28
108090000765 processed proteins & peptides Proteins 0.000 claims description 28
150000001413 amino acids Chemical class 0.000 claims description 26
230000002163 immunogen Effects 0.000 claims description 25
102000004196 processed proteins & peptides Human genes 0.000 claims description 24
229920001184 polypeptide Polymers 0.000 claims description 23
102000014914 Carrier Proteins Human genes 0.000 claims description 18
108010078791 Carrier Proteins Proteins 0.000 claims description 18
210000002966 serum Anatomy 0.000 claims description 17
241000588650 Neisseria meningitidis Species 0.000 claims description 12
238000003556 assay Methods 0.000 claims description 11
241000699670 Mus sp. Species 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 8
235000018417 cysteine Nutrition 0.000 claims description 7
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 5
101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 claims 1
229960005486 vaccine Drugs 0.000 abstract description 34
108700026633 Neisseria meningitidis factor H-binding Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 30
235000018102 proteins Nutrition 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 25
229940024606 amino acid Drugs 0.000 description 24
238000000034 method Methods 0.000 description 22
238000001179 sorption measurement Methods 0.000 description 11
IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 10
229940062780 lacto-n-neotetraose Drugs 0.000 description 10
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 9
101000874355 Escherichia coli (strain K12) Outer membrane protein assembly factor BamA Proteins 0.000 description 9
230000001948 anti-meningococcal effect Effects 0.000 description 9
-1 aromatic amino acids Chemical class 0.000 description 9
229910019142 PO4 Inorganic materials 0.000 description 8
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 8
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 8
230000021615 conjugation Effects 0.000 description 8
230000028993 immune response Effects 0.000 description 8
235000021317 phosphate Nutrition 0.000 description 8
241000529648 Neisseria meningitidis MC58 Species 0.000 description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 7
239000010452 phosphate Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
108010076504 Protein Sorting Signals Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000006640 acetylation reaction Methods 0.000 description 6
206010013023 diphtheria Diseases 0.000 description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
201000005702 Pertussis Diseases 0.000 description 5
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
244000052769 pathogen Species 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
206010043376 Tetanus Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
229940047712 aluminum hydroxyphosphate Drugs 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
229940031416 bivalent vaccine Drugs 0.000 description 4
238000010367 cloning Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
239000000463 material Substances 0.000 description 4
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
125000005629 sialic acid group Chemical group 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010060123 Conjugate Vaccines Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108010053187 Diphtheria Toxin Proteins 0.000 description 3
241000606768 Haemophilus influenzae Species 0.000 description 3
239000001361 adipic acid Substances 0.000 description 3
235000011037 adipic acid Nutrition 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229940031670 conjugate vaccine Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
231100000699 Bacterial toxin Toxicity 0.000 description 2
241000588832 Bordetella pertussis Species 0.000 description 2
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
108700018753 Neisseria porin Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
101710188053 Protein D Proteins 0.000 description 2
101710132893 Resolvase Proteins 0.000 description 2
108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
108010055044 Tetanus Toxin Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000000688 bacterial toxin Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
229960003983 diphtheria toxoid Drugs 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
101150002054 galE gene Proteins 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
238000002649 immunization Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229960005037 meningococcal vaccines Drugs 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
150000002482 oligosaccharides Chemical group 0.000 description 2
230000000625 opsonophagocytic effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 2
108010094020 polyglycine Proteins 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000010845 search algorithm Methods 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
239000008362 succinate buffer Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
229940118376 tetanus toxin Drugs 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
AKIIJJAKZRNOLW-HTIIIDOHSA-N (2r)-2-[di(hexadecanoyl)amino]-3-(2,3-dihydroxypropylsulfanyl)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N([C@@H](CSCC(O)CO)C(O)=O)C(=O)CCCCCCCCCCCCCCC AKIIJJAKZRNOLW-HTIIIDOHSA-N 0.000 description 1
PZFZLRNAOHUQPH-DJBVYZKNSA-N (2r)-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-2-(hexadecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CSC[C@H](OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PZFZLRNAOHUQPH-DJBVYZKNSA-N 0.000 description 1
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical group N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
229910017119 AlPO Inorganic materials 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
GMEXTMSAZLTIIH-BZTIHAFNSA-N C(C)(=O)N[C@@H](C(SCC(O)CO)(C(CCCCCCCCCCCCCCC)=O)C(CCCCCCCCCCCCCCC)=O)C(=O)O Chemical compound C(C)(=O)N[C@@H](C(SCC(O)CO)(C(CCCCCCCCCCCCCCC)=O)C(CCCCCCCCCCCCCCC)=O)C(=O)O GMEXTMSAZLTIIH-BZTIHAFNSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000034762 Meningococcal Infections Diseases 0.000 description 1
WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
101100165129 Neisseria meningitidis serogroup B (strain MC58) bamA gene Proteins 0.000 description 1
101100446533 Neisseria meningitidis serogroup B (strain MC58) fhbP gene Proteins 0.000 description 1
101100026367 Neisseria meningitidis serogroup B (strain MC58) nhhA gene Proteins 0.000 description 1
241001212279 Neisseriales Species 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101710084578 Short neurotoxin 1 Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
238000003917 TEM image Methods 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101710182532 Toxin a Proteins 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
FZLJPEPAYPUMMR-WLYGPBHPSA-N [(3S,4R,5S,6R)-3-[(2-deuterioacetyl)amino]-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound P(=O)(O)(O)OC1[C@@H](NC(C[2H])=O)[C@@H](O)[C@H](O)[C@H](O1)CO FZLJPEPAYPUMMR-WLYGPBHPSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
230000003679 aging effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001727 anti-capsular Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940001442 combination vaccine Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
229910000071 diazene Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000000600 disaccharide group Chemical group 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
150000002386 heptoses Chemical class 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000000569 multi-angle light scattering Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
RYRIMPODRHVEIW-UHFFFAOYSA-N n-(2-phenylethyl)nitramide Chemical compound [O-][N+](=O)NCCC1=CC=CC=C1 RYRIMPODRHVEIW-UHFFFAOYSA-N 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002245 particle Substances 0.000 description 1
108010021711 pertactin Proteins 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
GSHAAWZSAOJXLM-RQBQWGHISA-N phosphoethanolamine-Kdo2-lipid A Chemical group O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@H](O)[C@H](O[C@]3(O[C@@H]([C@H](O)[C@H](O)C3)[C@@H](CO)OP(O)(=O)OCCN)C(O)=O)C2)[C@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O GSHAAWZSAOJXLM-RQBQWGHISA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229940074404 sodium succinate Drugs 0.000 description 1
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

JP2014549542A 2011-12-29 2011-12-29 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ Pending JP2015505309A (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/IB2011/056006 WO2013098589A1 (en)	2011-12-29	2011-12-29	Adjuvanted combinations of meningococcal factor h binding proteins

Publications (2)

Publication Number	Publication Date
JP2015505309A true JP2015505309A (ja)	2015-02-19
JP2015505309A5 JP2015505309A5 (2)	2015-04-02

Family

ID=45529152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2014549542A Pending JP2015505309A (ja)	2011-12-29	2011-12-29	髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ

Country Status (7)

Country	Link
US (1)	US10596246B2 (2)
EP (1)	EP2797624A1 (2)
JP (1)	JP2015505309A (2)
AU (1)	AU2011384634A1 (2)
BR (1)	BR112014016223A8 (2)
CA (1)	CA2862247A1 (2)
WO (1)	WO2013098589A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2018521632A (ja) *	2015-06-02	2018-08-09	デスタートデルネーデルランデン，ヴェルト．ドールデミニステルヴァンヴイダブリューエスミニステリーヴァンボルクスゲツォントヘイト，ベルジーンエンシュポルトＤｅＳｔａａｔＤｅｒＮｅｄｅｒｌａｎｄｅｎ，Ｖｅｒｔ．ＤｏｏｒＤｅＭｉｎｉｓｔｅｒＶａｎＶｗｓＭｉｎｉｓｔｅｒｉｅＶａｎＶｏｌｋｓｇｅｚｏｎｄｈｅｉｄ，ＷｅｌｚｉｊｎＥｎＳｐｏｒｔ	グラム陰性外膜小胞における抗原の表面提示

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RU2013120302A (ru)	2010-10-01	2014-11-20	Модерна Терапьютикс, Инк.	Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru)	2011-10-03	2018-04-02	Модерна Терапьютикс, Инк.	Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh)	2011-12-16	2014-10-22	现代治疗公司	经修饰的核苷、核苷酸和核酸组合物
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en)	2012-11-26	2014-05-30	Moderna Therapeutics, Inc.	Terminally modified rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja)	2013-10-03	2016-12-15	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低密度リポタンパク質受容体をコードするポリヌクレオチド
GB201614687D0 (en) *	2016-08-31	2016-10-12	Univ Oxford Innovation Ltd	fHbp scaffold

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006521782A (ja) *	2002-11-22	2006-09-28	カイロンソチエタアレスポンサビリタリミタータ	髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4057685A (en)	1972-02-02	1977-11-08	Abbott Laboratories	Chemically modified endotoxin immunizing agent
US4673574A (en)	1981-08-31	1987-06-16	Anderson Porter W	Immunogenic conjugates
US4459286A (en)	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
US4663160A (en)	1983-03-14	1987-05-05	Miles Laboratories, Inc.	Vaccines for gram-negative bacteria
US4761283A (en)	1983-07-05	1988-08-02	The University Of Rochester	Immunogenic conjugates
US4808700A (en)	1984-07-09	1989-02-28	Praxis Biologics, Inc.	Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it)	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
US5204098A (en)	1988-02-16	1993-04-20	The United States Of America As Represented By The Department Of Health And Human Services	Polysaccharide-protein conjugates
NL8802046A (nl)	1988-08-18	1990-03-16	Gen Electric	Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
EP0378881B1 (en)	1989-01-17	1993-06-09	ENIRICERCHE S.p.A.	Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1991001146A1 (en)	1989-07-14	1991-02-07	Praxis Biologics, Inc.	Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en)	1990-08-13	1992-07-15	American Cyanamid Co	Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it)	1992-03-06	1996-07-22		Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en)	1992-07-30	1997-06-10	Yeda Res & Dev	Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PL175595B1 (pl)	1992-08-31	1999-01-29	North American Vaccine Inc	Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
US5425946A (en)	1992-08-31	1995-06-20	North American Vaccine, Inc.	Vaccines against group C Neisseria meningitidis
NL9201716A (nl)	1992-10-02	1994-05-02	Nederlanden Staat	Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US5698438A (en)	1994-10-18	1997-12-16	Oregon Health Sciences University	Bacterial hemoglobin receptor gene
IL117483A (en)	1995-03-17	2008-03-20	Bernard Brodeur	MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
WO1998053851A1 (en)	1997-05-28	1998-12-03	University Of Iowa Research Foundation	Laft mutants of pathogenic gram-negative bacteria
GB9713156D0 (en)	1997-06-20	1997-08-27	Microbiological Res Authority	Vaccines
US6645503B1 (en)	1998-03-10	2003-11-11	Wyeth Holdings Corporation	Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261352A3 (en)	1998-05-01	2012-01-04	Novartis Vaccines and Diagnostics, Inc.	Neisseria meningitidis antigens and compositions
JP2004505885A (ja)	1998-08-19	2004-02-26	ノース　アメリカン　ワクチン，　インコーポレイテッド	Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
WO2000023595A1 (en)	1998-10-22	2000-04-27	The University Of Montana	Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
AU762369B2 (en)	1998-11-03	2003-06-26	De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur	LPS with reduced toxicity from genetically modified gram negative bacteria
AU1626199A (en)	1998-12-04	2000-06-26	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	A vi-repa conjugate vaccine for immunization against salmonella typhi
ES2275499T3 (es)	1999-03-19	2007-06-16	Glaxosmithkline Biologicals S.A.	Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en)	1999-04-09	2000-10-19	Techlab, Inc.	Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP2003518363A (ja)	1999-04-30	2003-06-10	カイロンエセ．ピー．アー．	保存されたナイセリア抗原
US6531131B1 (en)	1999-08-10	2003-03-11	The United States Of America As Represented By The Department Of Health And Human Services	Conjugate vaccine for Neisseria meningitidis
GB9923176D0 (en)	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
CA2390344C (en)	1999-11-29	2014-08-26	Chiron Spa	85kda neisserial antigen
PL216780B1 (pl)	2000-01-25	2014-05-30	Univ Queensland Of Santa Lucia	Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
GB0007432D0 (en)	2000-03-27	2000-05-17	Microbiological Res Authority	Proteins for use as carriers in conjugate vaccines
AU2002309706A1 (en)	2001-05-11	2002-11-25	Aventis Pasteur, Inc.	Novel meningitis conjugate vaccine
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
MX339524B (es) *	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ATE419873T1 (de)	2002-02-22	2009-01-15	Ca Nat Research Council	Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
PT1777236T (pt)	2002-03-26	2017-02-13	Glaxosmithkline Biologicals Sa	Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
EP1524991A1 (en)	2002-08-02	2005-04-27	GlaxoSmithKline Biologicals S.A.	Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
US7785608B2 (en) *	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
MXPA05011110A (es)	2003-04-16	2006-01-24	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
GB0419408D0 (en)	2004-09-01	2004-10-06	Chiron Srl	741 chimeric polypeptides
CA2604363C (en)	2005-04-08	2015-06-16	Wyeth	Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en)	2005-04-08	2010-05-04	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en)	2005-04-08	2007-08-09	Wyeth	Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ562719A (en)	2005-04-08	2008-12-24	Wyeth Corp	Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation
US7955605B2 (en)	2005-04-08	2011-06-07	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US8398983B2 (en)	2005-06-27	2013-03-19	Glaxosmithkline Biologicals, S.A.	Immunogenic composition
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
PL1973564T3 (pl)	2005-12-22	2017-04-28	Glaxosmithkline Biologicals S.A.	Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
DE602007003596D1 (de)	2006-06-12	2010-01-14	Glaxosmithkline Biolog Sa	Impfstoff
PT2074221E (pt)	2006-10-10	2010-09-06	Wyeth Llc	Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2185576A4 (en)	2007-08-02	2011-01-12	Childrens Hosp & Res Ct Oak	FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
CN102356089B (zh)	2008-02-21	2014-02-19	诺华股份有限公司	脑膜炎球菌fHBP多肽
HUE049695T2 (hu) *	2009-03-24	2020-10-28	Glaxosmithkline Biologicals Sa	Adjuváló H meningococcus faktort kötõ fehérje
CA2803239A1 (en)	2010-06-25	2011-12-29	Novartis Ag	Combinations of meningococcal factor h binding proteins
KR101594228B1 (ko)	2010-08-23	2016-02-15	와이어쓰 엘엘씨	네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en)	2010-09-10	2014-11-28	Wyeth Llc	Non-lipidated variants of neisseria meningitidis orf2086 antigens

2011
- 2011-12-29 EP EP11811574.0A patent/EP2797624A1/en not_active Withdrawn
- 2011-12-29 JP JP2014549542A patent/JP2015505309A/ja active Pending
- 2011-12-29 CA CA2862247A patent/CA2862247A1/en not_active Abandoned
- 2011-12-29 BR BR112014016223A patent/BR112014016223A8/pt not_active IP Right Cessation
- 2011-12-29 WO PCT/IB2011/056006 patent/WO2013098589A1/en not_active Ceased
- 2011-12-29 US US14/368,957 patent/US10596246B2/en active Active
- 2011-12-29 AU AU2011384634A patent/AU2011384634A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006521782A (ja) *	2002-11-22	2006-09-28	カイロンソチエタアレスポンサビリタリミタータ	髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIANG HQ, ET AL.: "Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine t", VACCINE, vol. 28, no. 37, JPN6015044028, 2010, pages 6086 - 6093, XP027204839, ISSN: 0003187687 *
SEIB KL, ET AL.: "Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their", INFECTION AND IMMUNITY, vol. 79, no. 2, JPN6015044029, February 2011 (2011-02-01), pages 970 - 981, XP055121487, ISSN: 0003187688, DOI: 10.1128/IAI.00891-10 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2018521632A (ja) *	2015-06-02	2018-08-09	デスタートデルネーデルランデン，ヴェルト．ドールデミニステルヴァンヴイダブリューエスミニステリーヴァンボルクスゲツォントヘイト，ベルジーンエンシュポルトＤｅＳｔａａｔＤｅｒＮｅｄｅｒｌａｎｄｅｎ，Ｖｅｒｔ．ＤｏｏｒＤｅＭｉｎｉｓｔｅｒＶａｎＶｗｓＭｉｎｉｓｔｅｒｉｅＶａｎＶｏｌｋｓｇｅｚｏｎｄｈｅｉｄ，ＷｅｌｚｉｊｎＥｎＳｐｏｒｔ	グラム陰性外膜小胞における抗原の表面提示
JP7008900B2 (ja)	2015-06-02	2022-02-10	イントラヴァックビー．ブイ．	グラム陰性外膜小胞における抗原の表面提示

Also Published As

Publication number	Publication date
US10596246B2 (en)	2020-03-24
WO2013098589A1 (en)	2013-07-04
EP2797624A1 (en)	2014-11-05
AU2011384634A1 (en)	2014-06-19
US20150209419A1 (en)	2015-07-30
BR112014016223A8 (pt)	2017-07-04
CA2862247A1 (en)	2013-07-04
BR112014016223A2 (pt)	2017-06-13

Legal Events

Date	Code	Title	Description
2014-12-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141226
2014-12-27	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141226
2015-11-04	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151102
2016-01-29	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160129
2016-03-01	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160301
2016-04-01	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160401
2016-07-27	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160727

Publication	Publication Date	Title
US10568953B2 (en)	2020-02-25	Adjuvanting meningococcal factor H binding protein
US10596246B2 (en)	2020-03-24	Adjuvanted combinations of meningococcal factor H binding proteins
US10478483B2 (en)	2019-11-19	Combinations of meningococcal factor H binding proteins
US20120064103A1 (en)	2012-03-15	Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US20100189737A1 (en)	2010-07-29	Meningococcal vaccines including hemoglobin receptor
AU2014268243B2 (en)	2017-02-02	Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
AU2013202290A1 (en)	2013-05-02	Adjuvanting meningococcal factor H binding protein